Share
1,346 Posts.
lightbulb Created with Sketch. 17
clock Created with Sketch.
20/04/16
08:53
Share
Originally posted by rusty02
↑
Cane
My appologies. The IFD and SDA I referred to yesterday were the 3rd party auditors. Please understand that I was writing most of the discussion down and I may of miss understood the letters said. The IFD could be the IND but clearly understood these 2 identities to be auditors.
My final correspondence to Kym this morning,
Hi Kym,
Thank you for your time yesterday.
One final concern is many shareholders I spoke with yesterday feel that in fact there is a lacking of communication with investors. (no I’m not talking just about HC) This may have risen through the non disclosure of Graham Kelly departure and this non disclosure seems to be continued moving forward.
We feel that there is an issue with the company marketing protocols and would appreciate if your department understand the animosity with shareholder’s at present and act on this issue. I put forward an simple investor update written in “layman” terms of any recent milestone, company direction and corporate activities including any CEO review. This will entice a wider markets to look at our company with interest and appeal the information starved/hungry current holders. There is an issue here. I think you should look into this aspect of the marketing tools available for the better of our company profile. Doesn't have to be an update every week or on the dot every month but not to have any form of wider market approach as has happened in the last 10-12 months is clearly a concern.
Again thank you for your time
cheers
Expand
Thanks for that rusty,
I've been going over the Shareholder Communication Policy again and it is obvious to me that Novogen is working with the assumption that it is a clinical drug company. This assumption is currently false. Novogen has no drugs that are currently in the clinic. Novogen is presently a pre-clinical drug company.
Pre-clinical data is the only data that Novogen currently has and it is the only metric upon which "information that would help a reasonable person to decide ether to acquire, retain or dispose of the Company’s securities " can be obtained. This should be announced to the ASX/NASDAQ
Novogen has committed to following this guide, Code of Best Practice for Reporting by Life Science Companies , which states in the ASX listing rules disclosure section:
I don't think that any reasonable person would put Novogen in the 'mature company' box.
The reality is that pre-clinical data is materially significant for Novogen.